Peer Review Policy

In his article entitled "U.S. Research Environment Lures Canadian Scientists..." (The Scientist, May 1, 1989, page 9), Louis Siminovitch laments that persons "with less than the best qualifications" are appointed to peer review committees because of the policy of inclusion of persons from different Canadian geographical areas. According to Siminovitch, "inevitably, this means that the best scientists get shortchanged in their research funds." His prescriptions for reform include having only the

Written byDonald Forsdyke
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Whatever the explanation, it is inevitable that persons with "less than the best qualifications" do get on review committees. This need not be so bad as Siminovitch would have us believe. He should recognize that, even if we had the "best" on review committees, the process of deciding who is the most deserving of funding is highly error prone. If the committees were simply deciding who had the best track record, this might not be so. But the committees are asked to evaluate ideas. The fact that a process is error prone means that we should not place great confidence in it. This should be taken into account in System design.

The worst solution would be to narrow the funding base, as Siminovitch proposes. This would mean that the "best" projects, by Siminovitch's lights, might fall below the funding cutoff line. Rather, there should be a sliding scale of funding, ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies